SCHEMBL4587709

SCHEMBL4587709

N=C(N)NCCC[C@H](NC(=O)CN)C(=O)[O-].N=C(N)NCCC[C@H](NC(=O)CN)C(=O)[O-].[Mn+2]

nearest known ligand 0.36

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ NPY4R P50391 15/20 0.36
▸ NPY1R P25929 10/20 0.36
▸ NPY5R Q15761 9/20 0.36
▸ NPY2R P49146 6/20 0.36
▸ C3AR1 Q16581 1/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ MEN1 O00255 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ SLC15A2 Q16348 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2815692 0.97 NPY4R (0.36) NPY4RNPY1RNPY5RNPY2RC3AR1
SCHEMBL4589289 0.90 NMT1 (0.42) NPY4RNPY1RNPY5RNPY2RSLC15A2
SCHEMBL2241867 0.87 NMT1 (0.42) NPY4RNPY1RNPY5RNPY2RSLC15A2
SCHEMBL1627262 0.86 NPY4R (0.43) NPY4RNPY1RNPY5RNPY2RC3AR1
SCHEMBL29476474 0.85 C3AR1 (0.45) NPY4RNPY1RNPY5RNPY2RC3AR1
SCHEMBL2116832 0.85 C3AR1 (0.45) NPY4RNPY1RNPY5RNPY2RC3AR1
SCHEMBL187696 0.85 C3AR1 (0.45) NPY4RNPY1RNPY5RNPY2RC3AR1
SCHEMBL2815688 0.84 C3AR1 (0.44) NPY4RNPY1RNPY5RNPY2RC3AR1
SCHEMBL4587702 0.84 C3AR1 (0.44) NPY4RNPY1RNPY5RNPY2RC3AR1
SCHEMBL5160379 0.83 NPY4R (0.35) NPY4RNPY1RNPY5RNPY2RC3AR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255032-A1 METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN PROCYTE CORPORATION (US) 2008-10-16 — — US disclosed
US-7384916-B2 Methods and compositions for preventing and treating aging or photodamaged skin PROCYTE CORPORATION (US) 2008-06-10 — — US disclosed
US-20060246029-A1 Methods and compositions for preventing and treating aging or photodamaged skin PROCYTE CORPORATION (US) 2006-11-02 — — US disclosed
US-20060018851-A1 Methods and compositions for preventing and treating hyperpigmentation of skin PROCYTE CORPORATION (US) 2006-01-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060246029-A1 Methods and compositions for preventing and treating aging or photodamaged skin RBP1, RBP4, SOD1 NPY4R 3564/4885NPY1R 2475/4885NPY5R 2478/4885
US-20060018851-A1 Methods and compositions for preventing and treating hyperpigmentation of skin RBP1, RBP4, MC1R NPY4R 3166/4885NPY1R 1480/4885NPY5R 1383/4885
US-20080255032-A1 METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN RBP1, RBP4, SOD1 NPY4R 3564/4885NPY1R 2475/4885NPY5R 2478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback